GlaxoSmithKline (GSK) and Innoviva Inc. recently released positive results for a study evaluating Relvar Ellipta in treating asthma.
According to GSK, the results of the study show that patients with well-controlled asthma could switch from the twice-daily Seretide Accuhaler (fluticasone propionate /salmeterol, FP/SAL) 250/50, without compromising their lung function to the once-daily Relvar Ellipta (fluticasone furoate/vilanterol, FF/VI) 100/25, an inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA) combination.
“At GSK we are constantly searching for ways in which we can help patients better manage their asthma," Eric Dube, global Head of Respiratory Franchise for GSK, said in a statement. “In this positive study we have demonstrated non-inferiority for once-daily Relvar vs. twice-daily Seretide on lung function. This gives us confidence that for patients who struggle taking a twice-daily treatment regimen, there may be a once-daily treatment option available, providing greater physician choice to help patients.”
GSK plans to submit the data from the study to the European Medicines Agency.
“We believe the results of this study are important for patients and physicians,” Innoviva CEO Mike Aguiar said.
Alerts Sign-up